Turkey's Social Security Institution (SGK, Sosyal Güvenlik Kurumu) published Announcement 2026/33 on August 26, 2026, amending the Bedeli Ödenecek İlaçlar Listesi (List of Reimbursable Pharmaceuticals) under Article 12 of the Drug Reimbursement Regulation and the SUT (Sağlık Uygulama Tebliği). The annexes are dated August 28, 2026, taking effect two days after publication and leaving a narrow window for marketing authorisation holders, hospital pharmacies and SGK-contracted community pharmacies to reconcile their formularies.
The announcement carries the standard Article 12 instruments: a PDF notice ("12. MADDE DUYURUSU 28.08.2026.pdf") and an XLSX workbook ("28.08.2026 12.MADDE-YAYIM.xlsx") listing the additions, activations, passivations and removals applied to the EK-4/A annex. In Turkey's reimbursement system, an EK-4/A entry is market-access blocking: a product absent from the list cannot be reimbursed by SGK, and a passivated entry signals that the reimbursement rate or conditions have changed.
What did SGK change in the reimbursable list?
Announcement 2026/33 is the latest installment in the weekly to biweekly Article 12 duyuru (announcement) series that maintains the EK-4/A annex. Each installment applies four operation types to the live reimbursable list:
| Operation | Effect on reimbursement |
|---|---|
| Addition | New product or presentation becomes SGK-reimbursable |
| Activation | Previously passive entry reinstated for reimbursement |
| Passivation | Entry moved to passive status; reimbursement rate or conditions change |
| Removal | Product no longer reimbursable through SGK |
The full set of affected products, ATC codes and reimbursement rates sits in the 28.08.2026 12.MADDE-YAYIM.xlsx annex, which practitioners should diff against the prior list state. The governing notice is the 12. MADDE DUYURUSU 28.08.2026.pdf, and the SGK duyuru page carries both files.
Who is impacted, and by when must they act?
The August 28, 2026 application date binds every actor that dispenses or claims reimbursement for a listed medicine. Marketing authorisation holders (MAHs), both Turkish and multinational, selling into the Turkish reimbursement market must verify whether their products moved between active and passive status. Hospital pharmacy procurement teams must update formularies and procurement lists to match the new active set. SGK-contracted community pharmacies (eczane) must align their point-of-service reimbursement claims with the updated rates.
Because the application date lags publication by only two days, the practical review window is one to two business days. Teams that wait until the August 28 effective date risk dispensing or claiming against a list state SGK no longer honours, which triggers claim rejections and rework.
How does this fit Turkey's reimbursement architecture?
Turkey splits medicines regulation across three bodies, a structure international trackers often miss. TİTCK (Türkiye İlaç ve Tıbbi Cihaz Kurumu) grants marketing authorisation. The Ministry of Health coordinated Pricing Evaluation Commission (Fiyat Değerlendirme Komisyonu) sets the list price. SGK, via the SUT list and the TEDK (Tıbbi ve Ekonomik Değerlendirme Komisyonu) clinical and pharmacoeconomic evaluation, decides reimbursement. Turkey has no standalone HTA agency; the clinical and economic assessment runs inside SGK. An Article 12 duyuru is the operational output of that chain: it is the instrument that moves products on and off the only list that opens reimbursement.
This same series produced announcements 2026/30, 2026/31 and 2026/32 earlier in August 2026, with 2026/32 dated August 19, 2026. The cadence is weekly to biweekly, so market-access teams should expect the next installment within the same rhythm rather than treating 2026/33 as a one-off.
Obsidian's continuous, per-jurisdiction real-time monitoring surfaces this kind of change the moment SGK publishes it, rather than when a quarterly digest catches up.
Take advantage of this real-time watch
- Download the 28.08.2026 12.MADDE-YAYIM.xlsx annex and diff it against your portfolio: flag any product moved to passivation or removal, and any newly added or activated product.
- Confirm reimbursement rates for newly added or activated products and update pricing, tender and procurement systems before August 28, 2026.
- Brief hospital pharmacy and procurement teams on the updated active set so dispensing and claims align with the list SGK will enforce from August 28.
- Track the next Article 12 duyuru in the series, expected within one to two weeks, and re-run the diff against the new annex.
The announcement is live on the SGK site, and the annexes apply from August 28, 2026. Verify applicability against your portfolio, check the August 28 deadline, and brief the relevant team before the effective date passes.
